FDA Will Pull Vet Drug Used in Pork Industry Over Cancer Concerns for Humans
By Physician’s Briefing Staff HealthDay Reporter
WEDNESDAY, Nov. 8, 2023 -- The U.S. Food and Drug Administration said Tuesday that it plans to pull a veterinary drug used commonly in the pork industry because it might pose a cancer risk to humans who eat pig products.
The antimicrobial, carbadox (Mecadox), is typically added to pig feed to fight infections and fatten up the animals. But pork contaminated with "carcinogenic residues" from the drug could wind up in foods like hot dogs and cold cuts, though the agency stressed in its notice that it is not telling people to change their food choices at the moment.
The FDA concerns with carbadox date back decades: When it was first approved in 1998, the agency's worries were abated by a strategy that involved testing edible parts of pigs that had been given carbadox. According to the agency, data now show that those testing methods do not adequately measure the cancer risk posed by pork produced while using the drug.
Drug maker Phibro Animal Health Corp. said Tuesday it was "extremely disappointed" by the latest FDA move. "While Phibro has continuously offered to meet with FDA to discuss the regulatory method and has offered viable alternative methods currently being used in other countries, it is clear that, instead, the FDA is ignoring the long history of safety that Phibro has established and reaffirmed through its most recent studies," the company said in a news release.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Vaginal Cancer Incidence Increasing Globally
WEDNESDAY, July 3, 2024 -- The incidence of vaginal cancer is increasing globally, according to a study published online June 25 in BJOG: An International Journal of Obstetrics...
Nudging Both Clinicians, Patients May Increase Serious Illness Conversations
TUESDAY, July 2, 2024 -- Combining clinician- and patient-directed nudges may help to promote serious illness conversations (SICs) in cancer care, according to a study published...
Perioperative Chemo Improves Progression-Free Survival in Pancreatic Cancer
TUESDAY, July 2, 2024 -- For patients with resectable pancreatic ductal adenocarcinoma (PDAC), the 12-month progression-free survival (PFS) may be increased with neoadjuvant...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.